Technical Analysis
Comprehensive insights into market trends, chart patterns, and key indicators. Equip yourself with the tools and strategies to make data-driven trading decisions.
Two new Premium Bonds millionaires from Yorkshire emerged in February’s draw, highlighting the enduring appeal of this unique savings method. Millions in unclaimed prizes remain, so check your bonds – you could be a winner!
UK Premium Bonds February Draw: Two New Millionaires Emerge in Yorkshire Read More »
Trump’s tariff announcement sparked market volatility, impacting pound, gold, and oil prices. Analyze the effects on these assets and understand the implications of escalating trade tensions on global markets.
Market Volatility After Trump’s Tariff Announcement: Impacts on Pound, Gold, and Oil Read More »
Palantir’s Q4 earnings are out Monday, with investors focused on AI platform performance and conversion of pilot programs to deals. Analysts expect revenue between $767-771 million, following a strong Q3 and amidst global market volatility.
Palantir Earnings Preview: Q4 Results and AI Platform in Focus Read More »
Wall Street predicts continued US economic dominance in 2025, citing its resilient, diverse economy and strong growth potential. Goldman Sachs and JPMorgan urge investors to maintain faith in American exceptionalism and its leading position.
US Economic Dominance Set to Continue in 2025, Wall Street Giants Predict Read More »
FRUZAQLA (fruquintinib) is now approved in Canada for metastatic colorectal cancer (mCRC) patients who have exhausted standard therapies. This new oral VEGFR inhibitor significantly improves survival in patients previously treated with multiple regimens, offering a new hope.
Fruzaqla Approved in Canada for Metastatic Colorectal Cancer Read More »
Euro area inflation hits 2.5% in January, fueled by rising service and food costs. This poses a challenge for the ECB, which is considering further interest rate cuts amid trade tensions with the US.
Euro Area Inflation Rises to 2.5% in January, Challenging ECB Policy Read More »
Foot Locker’s Q3 CY2024 earnings missed estimates, with EPS of $0.33 vs. $0.40 and revenue down 1.4% year-on-year. Despite a 2.4% same-store sales increase, lowered guidance and weak financials raise concerns.
Foot Locker’s Q3 Earnings Miss: A Deep Dive into Performance and Future Outlook Read More »
Acelyrin’s lonigutamab showed promise in Phase II trials for thyroid eye disease, reducing proptosis and improving vision. However, revised dosing for Phase III and a delayed timeline contribute to investor skepticism.
Starbucks enhances the customer experience with free refills for all, self-serve condiment bars, and a revised open-door policy. These changes prioritize the in-store experience while aiming to create a more welcoming environment.
Billionaire Stanley Druckenmiller’s top holding is Natera (NTRA), a leading genetic testing company. Druckenmiller’s significant investment reflects strong confidence in Natera’s growth potential and innovative healthcare solutions.
Stanley Druckenmiller’s Top Holding: A Deep Dive into Natera (NTRA) Read More »
